CN112386614A - 植物乳杆菌ma2在制备预防或改善阿尔茨海默症药物或食品方面中的应用 - Google Patents
植物乳杆菌ma2在制备预防或改善阿尔茨海默症药物或食品方面中的应用 Download PDFInfo
- Publication number
- CN112386614A CN112386614A CN202011339029.4A CN202011339029A CN112386614A CN 112386614 A CN112386614 A CN 112386614A CN 202011339029 A CN202011339029 A CN 202011339029A CN 112386614 A CN112386614 A CN 112386614A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus plantarum
- food
- medicine
- group
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 73
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 73
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 73
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 37
- 235000013305 food Nutrition 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 title claims abstract description 27
- 241000894006 Bacteria Species 0.000 claims abstract description 13
- 239000002552 dosage form Substances 0.000 claims abstract description 8
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 230000000968 intestinal effect Effects 0.000 claims description 17
- 230000002757 inflammatory effect Effects 0.000 claims description 12
- 210000002569 neuron Anatomy 0.000 claims description 12
- 230000001965 increasing effect Effects 0.000 claims description 11
- 241000606125 Bacteroides Species 0.000 claims description 10
- 241000605861 Prevotella Species 0.000 claims description 10
- 210000005013 brain tissue Anatomy 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 230000019491 signal transduction Effects 0.000 claims description 10
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 230000003959 neuroinflammation Effects 0.000 claims description 9
- 230000009286 beneficial effect Effects 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 7
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 6
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 6
- 238000013518 transcription Methods 0.000 claims description 6
- 230000035897 transcription Effects 0.000 claims description 6
- 241000611330 Chryseobacterium Species 0.000 claims description 5
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 claims description 5
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 235000015141 kefir Nutrition 0.000 claims description 4
- 238000009629 microbiological culture Methods 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 230000002314 neuroinflammatory effect Effects 0.000 claims description 4
- 230000001575 pathological effect Effects 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 230000007470 synaptic degeneration Effects 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 244000005700 microbiome Species 0.000 claims description 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 claims 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 claims 1
- 241000252212 Danio rerio Species 0.000 description 60
- 210000004556 brain Anatomy 0.000 description 18
- 230000000694 effects Effects 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 8
- 230000003542 behavioural effect Effects 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 6
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 229940072040 tricaine Drugs 0.000 description 6
- FQZJYWMRQDKBQN-UHFFFAOYSA-N tricaine methanesulfonate Chemical compound CS([O-])(=O)=O.CCOC(=O)C1=CC=CC([NH3+])=C1 FQZJYWMRQDKBQN-UHFFFAOYSA-N 0.000 description 6
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 5
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 241000186000 Bifidobacterium Species 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000000274 microglia Anatomy 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 3
- 102000003714 TNF receptor-associated factor 6 Human genes 0.000 description 3
- 108090000009 TNF receptor-associated factor 6 Proteins 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 230000006886 spatial memory Effects 0.000 description 3
- 102000012440 Acetylcholinesterase Human genes 0.000 description 2
- 108010022752 Acetylcholinesterase Proteins 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 2
- 241001098657 Pterois Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 229940022698 acetylcholinesterase Drugs 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000003736 gastrointestinal content Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- 208000006888 Agnosia Diseases 0.000 description 1
- 241001047040 Agnosia Species 0.000 description 1
- 102100040121 Allograft inflammatory factor 1 Human genes 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 102000034342 Calnexin Human genes 0.000 description 1
- 108010056891 Calnexin Proteins 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000589565 Flavobacterium Species 0.000 description 1
- 101000890626 Homo sapiens Allograft inflammatory factor 1 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 241000425347 Phyla <beetle> Species 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000007131 anti Alzheimer effect Effects 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 210000004766 cell nucleus structure Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000010855 food raising agent Nutrition 0.000 description 1
- 230000007149 gut brain axis pathway Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 230000006951 hyperphosphorylation Effects 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000006724 microglial activation Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011339029.4A CN112386614B (zh) | 2020-11-25 | 2020-11-25 | 植物乳杆菌ma2在制备预防或改善阿尔茨海默症药物或食品方面中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011339029.4A CN112386614B (zh) | 2020-11-25 | 2020-11-25 | 植物乳杆菌ma2在制备预防或改善阿尔茨海默症药物或食品方面中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112386614A true CN112386614A (zh) | 2021-02-23 |
CN112386614B CN112386614B (zh) | 2022-11-08 |
Family
ID=74603850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011339029.4A Active CN112386614B (zh) | 2020-11-25 | 2020-11-25 | 植物乳杆菌ma2在制备预防或改善阿尔茨海默症药物或食品方面中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112386614B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022131192A1 (ja) * | 2020-12-16 | 2022-06-23 | 株式会社明治 | 脳組織の炎症改善用組成物 |
CN115414391A (zh) * | 2022-09-29 | 2022-12-02 | 天津科技大学 | 植物乳杆菌ma2在制备预防或改善由腺嘌呤诱导的慢性肾脏疾病中的应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1798831A (zh) * | 2003-04-04 | 2006-07-05 | 普罗比公司 | 含有与丹宁组合的植物乳杆菌菌株的组合物和新植物乳杆菌菌株 |
CN101559082A (zh) * | 2009-06-01 | 2009-10-21 | 天津科技大学 | 一种降血脂及调节肠道菌群的益生菌制剂的制备方法 |
CN104781390A (zh) * | 2012-08-16 | 2015-07-15 | 庆熙大学校产学协力团 | 具有对衰老及痴呆的预防和/或治疗活性的乳酸菌 |
CN111202754A (zh) * | 2019-03-11 | 2020-05-29 | 江苏佰澳达生物科技有限公司 | 一种预防和改善老年痴呆症的益生菌组合物及其应用 |
-
2020
- 2020-11-25 CN CN202011339029.4A patent/CN112386614B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1798831A (zh) * | 2003-04-04 | 2006-07-05 | 普罗比公司 | 含有与丹宁组合的植物乳杆菌菌株的组合物和新植物乳杆菌菌株 |
CN102210717A (zh) * | 2003-04-04 | 2011-10-12 | 普罗比公司 | 含有与丹宁组合的植物乳杆菌菌株的组合物和新植物乳杆菌菌株 |
CN101559082A (zh) * | 2009-06-01 | 2009-10-21 | 天津科技大学 | 一种降血脂及调节肠道菌群的益生菌制剂的制备方法 |
CN104781390A (zh) * | 2012-08-16 | 2015-07-15 | 庆熙大学校产学协力团 | 具有对衰老及痴呆的预防和/或治疗活性的乳酸菌 |
CN111202754A (zh) * | 2019-03-11 | 2020-05-29 | 江苏佰澳达生物科技有限公司 | 一种预防和改善老年痴呆症的益生菌组合物及其应用 |
Non-Patent Citations (3)
Title |
---|
FENGWEI TIAN ET AL.: "The therapeutic protection of a living and dead Lactobacillus strain against aluminum-induced brain and liver injuries in C57BL/6 mice", 《PLOS ONE》 * |
LEILEI YU ET AL.: "Lactobacillus plantarum CCFM639 can prevent aluminium-induced neural injuries and abnormal behaviour in mice", 《JOURNAL OF FUNCTIONAL FOODS》 * |
MIJIN KWON ET AL.: "Exopolysaccharide Isolated from Lactobacillus plantarum L-14 Has Anti-Inflammatory E ects via the Toll-Like Receptor 4 Pathway in LPS-Induced RAW 264.7 Cells", 《INT. J. MOL. SCI.》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022131192A1 (ja) * | 2020-12-16 | 2022-06-23 | 株式会社明治 | 脳組織の炎症改善用組成物 |
CN115414391A (zh) * | 2022-09-29 | 2022-12-02 | 天津科技大学 | 植物乳杆菌ma2在制备预防或改善由腺嘌呤诱导的慢性肾脏疾病中的应用 |
CN115414391B (zh) * | 2022-09-29 | 2024-03-19 | 天津科技大学 | 植物乳杆菌ma2在制备预防或改善由腺嘌呤诱导的慢性肾脏疾病药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN112386614B (zh) | 2022-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2998877C (en) | Lactobacillus johnsonii strain and use thereof for prevention and treatment of degenerative brain diseases or cognitive function disorders | |
CN110835616B (zh) | 副干酪乳杆菌gks6的活性物质、含其的组合物及其促进长寿的用途 | |
CN112386614B (zh) | 植物乳杆菌ma2在制备预防或改善阿尔茨海默症药物或食品方面中的应用 | |
KR20110057550A (ko) | 치매, 치매관련 질환의 예방/치료 및 인지기능장애 개선에 효과가 있는 유산균 발효 산물, 이의 제조방법 및 용도 | |
CN115039883B (zh) | 使用植物乳杆菌tsp05分离株来降低嘌呤含量以及尿酸水平 | |
CN115109734B (zh) | 一株具有缓解高尿酸功能敏捷乳杆菌b13t4及其应用 | |
CN114410547B (zh) | 一株能促进5-htp分泌及缓解抑郁的戊糖乳杆菌lpq1及其应用 | |
CN110833565A (zh) | 植物乳杆菌gkm3的活性物质、含其的组合物及其促进长寿的用途 | |
CN115992075A (zh) | 一株可抑制致病菌和促排便的鼠李糖乳杆菌及其应用 | |
CN116270756A (zh) | 嗜黏蛋白阿克曼氏菌及其药物组合物在改善和治疗神经退行性疾病中的应用 | |
CN110835615B (zh) | 乳双歧杆菌gkk2的活性物质、含其的组合物及其促进长寿的用途 | |
KR102404656B1 (ko) | 비피도박테리움 애니멀리스 서브스페시스 락티스 hy8002균주를 함유하는 인지기능장애 및 우울증 예방, 개선 또는 치료용 조성물 | |
CN117264810A (zh) | 一种具有改善代谢综合征功能的益生菌组合物及其应用 | |
JP2021526526A (ja) | 細菌株を含む組成物 | |
US20230338439A1 (en) | Composition for treating brain disease comprising pediococcus inopinatus or extracellular vesicles isolated therefrom as active ingredient | |
TWI793595B (zh) | 益生菌胞外泌體及其用途 | |
CN112915108B (zh) | 凝结芽孢杆菌ja845在制备预防和/或治疗阿尔茨海默病药物中的应用 | |
US20220088095A1 (en) | METHOD FOR REGULATING EXPRESSION OF IL-1b GENE, MMP1a GENE AND TIMP1 GENE OF CHONDROCYTES USING LACTOBACILLUS PLANTARUM STRAIN TCI227 | |
CN118222464B (zh) | 一种植物乳植杆菌及其在降尿酸的产品中的应用 | |
AU2019101449A4 (en) | Use of Lactobacillus brevis ProGA28 and its metabolites in the treatment or improvement of sleep disorders | |
US11510949B2 (en) | Use of the treatment or improvement of sleep disorders by Lactobacillus brevis ProGA28 and/or its metabolites | |
KR102404658B1 (ko) | 락토바실러스 카제이 hy2782 균주를 함유하는 인지기능장애 및 우울증 예방, 개선 또는 치료용 조성물 | |
CN117653673A (zh) | 一株能够缓解机体衰老症状的植物乳杆菌及其应用 | |
KR20240110171A (ko) | 지방세포의 지방축적 억제능을 갖는 Lactobacillus reuteri KCL018 균주, 이의 배양액 또는 균체 추출물을 포함하는 조성물 | |
CN116390739A (zh) | 包含沙克乳酸杆菌probio-65的用于预防或治疗阿尔茨海默病的组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20210223 Assignee: TIANJIN INNCORIGIN BIOLOGICAL TECHNOLOGY Co.,Ltd. Assignor: TIANJIN University OF SCIENCE AND TECHNOLOGY Contract record no.: X2023980036364 Denomination of invention: Application of Lactiplantibacillus plantarum MA2 in the preparation of drugs or foods to prevent or improve Alzheimer's disease Granted publication date: 20221108 License type: Common License Record date: 20230608 |